HC Wainwright reaffirmed their buy rating on shares of Caladrius Biosciences (NASDAQ:CLBS) in a research report report published on Tuesday, MarketBeat Ratings reports. The analysts noted that the move was a valuation call.
Separately, Zacks Investment Research lowered Caladrius Biosciences from a hold rating to a sell rating in a research report on Wednesday, January 10th.
Caladrius Biosciences (CLBS) opened at $5.55 on Tuesday. The stock has a market capitalization of $50.86, a price-to-earnings ratio of 2.63 and a beta of 1.46. Caladrius Biosciences has a 12-month low of $2.63 and a 12-month high of $7.79.
TRADEMARK VIOLATION WARNING: “Caladrius Biosciences (CLBS) Rating Reiterated by HC Wainwright” was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US & international trademark & copyright law. The correct version of this report can be accessed at https://www.tickerreport.com/banking-finance/3252967/caladrius-biosciences-clbs-rating-reiterated-by-hc-wainwright.html.
Caladrius Biosciences Company Profile
Caladrius Biosciences, Inc is a cell therapy development company with product candidates in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s lead product candidate, CLBS03, is a T regulatory cell (Treg) clinical Phase II therapy targeting adolescents with recent-onset type 1 diabetes mellitus (T1DM) using the patient’s own numerically and functionally enhanced Tregs.
Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.